RxDoctor Payments Data

Trenton Watson, NP

Nurse Practitioner · Smiths Station, ALNPI 1215475306

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 68 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$839
  • IBSA Pharma Inc.$94
  • Amgen$78
  • Scilex Pharmaceuticals Inc.$72
  • Biohaven Pharmaceuticals, Inc.$69
  • Arbor Pharmaceuticals, Inc.$69
  • plus $266 from 9 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,486 in reported general payments places this provider in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$75,783
Medicare patients
277
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate21$34,759
UbrelvyUbrogepant16$26,023
Diclofenac Sodium172$13,020
LinzessLinaclotide22$11,834
Lidocaine125$10,893
Gabapentin858$10,259
Buprenorphine31$8,090
Pregabalin403$7,247
Celecoxib295$5,493
Tizanidine Hcl680$5,314
ZtlidoLidocaine14$4,963
MovantikNaloxegol Oxalate12$4,820
Cyclobenzaprine Hcl418$4,600
Baclofen302$3,414
Ondansetron OdtOndansetron56$3,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Linzess$12$37,85738 claims
Scilex Pharmaceuticals Inc.Ztlido$72$4,96314 claims
Redhill Biopharma Inc.Movantik$41$4,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Smiths Station

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →